On 29 June 2006, a 65 year old woman fell ill with vomiting and diarrhoea in southern Finland
Objectives RA and its medication, especially TNF-α inhibitors, increase the risk of clinical tuberculosis (TB) infection. We aimed to investigate the clinical manifestations, incidence and temporal changes in TB occurring concurrently with rheumatic diseases (RDs) between 1995 and 2007. Methods We combined the register of the Social Insurance Institution of Finland and the National Infectious Disease Register to find adult patients with reimbursed DMARDs and with a TB notification between 1995 and 2007. After reviewing the medical records, we described their clinical manifestations and medications, explored TB incidence trends using Poisson regression, and compared the incidence of TB with that of the general population. Results We identified 291 patients with both TB and rheumatic disease (RD), 196 of whom had RA. Between 1995 and 2007, the incidence of TB in adult RD decreased from 58.8 to 30.0 per 100 000 (trend P < 0.001, average marginal effect −3.4/100 000 per year, 95% CI −4.4, −2.4). Compared with the general population, the incidence was ∼4-fold. Among RD patients, pulmonary TB was the most common form of TB (72.6%). Disseminated TB was present in 56 (19.6%) patients. Conclusion The incidence of TB among RD patients was ∼4-fold that of the general population, and it declined between 1995 and 2007. Disseminated TB was present in nearly 20% of patients.
Background The treatment of JIA has become more effective by means of biological disease modifying antirheumatic drugs (DMARDs). Biological DMARDs, however, increase the risk of infections. Objectives The aim of the study is to find out the incidence and the individual risk factors for bloodstream infections in JIA. Methods The Social Insurance Institution (SII) register of reimbursement of medicines and National Infectious Disease Register (National Institute of Health and Welfare) were used to identify JIA patients aged 2-18 years hospitalized for BSI during the years 2004-2011. Antirheumatic treatment of JIA was searched by using SII nationwide register. We also analysed the incidence of BSI in JIA patients with new diagnosis during the study period, and compared it with BSI in Finnish population of same age and study period. Results By means of combination of the register data we found a total of 10 patients (11 episodes) with BSI during the study period. The median age of children was 14 years. One patient had two distinct episodes of BSI. Pneumonia was the most common focus of infection. The following bacteria were detected: Staphylococcus aureus (4 cases), Streptococcus pneumoniae (3 cases), Staphylococcus epidermidis, Escherichia coli, Fusobacterium necroforum and Pseudomonas aeruginosa in one patient, respectively. Six patients were on biological DMARD and four on glucocorticoid treatment. We identified 1604 patients with JIA diagnosed in 2004-2011 with 6630 patient years of follow-up. Five JIA patients (7.5 infections/10 000 patient years, 95% CI 2.4 – 17.6) and 2184 control population subjects (2.8 infections/ 10 000 patient years, 95% CI 2.7 – 2.9) had BSI. Conclusions Bloodstream infections seem to be rare in patients with JIA. Interestingly, half of the patients with BSI were on biological DMARDs. Compared with control population, the standardized incidence ratio for BSI in JIA patients was 3.0 (95% CI 1.25 – 7.20). References Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010;6:561-571. Beukelman T, Xie F, Chen L et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:2773-2780. Disclosure of Interest None Declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.